Malaysia's Health Ministry (MOH) will require Product Registration Holders (PRHs) to report any disruptions or discontinuations in medicine supply starting July 1, 2026 [1, 2, 3]. PRHs must notify the ministry at least six months in advance of potential supply disruptions. If disruptions occur unexpectedly, immediate reporting is mandatory [1, 2, 3].
The National Pharmaceutical Regulatory Agency (NPRA) will publish this information in the Medicine Shortage and Discontinuation Database. The database will be accessible to industry players, healthcare professionals, and the public to enhance transparency [1, 2, 3].
MOH has introduced mitigation measures aimed at reducing supply risks. These include diversifying supply sources from alternative countries registered with the Drug Control Authority, lessening dependence on any single supplier [1, 2, 3].
Despite Sabah's unique geographical challenges, medicine supply levels in the state's public healthcare system remain stable and under control [1, 2, 3]. The ministry is strengthening inventory management and stock availability at healthcare facilities, especially in rural and hard-to-reach areas of Sabah [1, 2, 3]. Efforts are ongoing to enhance Sabah's pharmaceutical logistics hub and distribution network to improve storage efficiency and delivery to hospitals and clinics across the state [1, 2, 3].
Contingency plans include emergency distribution and stock mobilization between facilities to address local shortages caused by weather or transport disruptions [1, 2, 3].
Datuk Shahelmey Yahya (BN-Putatan) raised questions regarding mechanisms to ensure the supply chain of imported medicines remains unaffected and the readiness of Sabah's medicine security preparations [3].
The mandatory reporting requirement will take effect July 1, 2026, with PRHs obligated to provide six months' advance notice for anticipated supply disruptions [1, 2, 3].
